Generic Competition for Dimethyl Fumarate
Mar 03, 2022•3 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.
To hear the full podcast: https://www.neurology.org/podcast
For the best experience, listen in Metacast app for iOS or Android